Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Akers Biosciences third-quarter revenues up 10%

The figures were buoyed by sales of its breathalyser products and its rapid cholesterol tests
heparin test
Akers has developed a rapid test that can quickly diagnose an allergy to a common blood thinner

Diagnostics specialist Akers Biosciences, Inc.(LON:AKR, NASDAQ:AKER) said its third quarter revenues grew 10% to US$675,831, buoyed by sales of its breathalyser products and its rapid cholesterol tests.

It also said the commercial performance of its core product, used to spot allergic reactions to the blood thinner heparin, was “robust”. However it also noted demand for the IFA Heparin/PF4 Rapid Assay product had “plateaued” somewhat in the three months.

READ: Akers Bio expects sales of its ‘morning after’ alcohol breath test to ramp up as distributor secures major new channel partner

“The company is not satisfied with the plateau in sales of rapid HIT tests, which were broadly flat in the US during the third quarter, and is actively campaigning to drive future growth by pursuing further clinical pathway studies, heparin-induced thrombocytopenia awareness campaigns and a strategic focus on surgeons who are central to any decision to test for heparin platelet factor 4 antibodies,” investors were told.

As might be expected for company at this critical juncture in its commercial development Akers was loss-making. The pre-tax deficit was US$1.18mln.

READ: Akers Bio sees 'material commercial growth' for Heparin allergy test

That said, cash burn is starting to recede while the company boosted its coffers by US$680,748 after certain investors converted their warrants to shares.

Turnover for the nine months were also up 10% at US$2.54mln, with US$1.98mln of that total from the sales of the heparin test kit.

View full AKR profile View Profile

Akers Biosciences, Inc. Timeline

Related Articles

Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use